扩展版CPIC指南:基于G6PD基因型的用药指导
该指南由临床药物基因组学实施联盟(CPIC)制定,基于系统综述和监管警告,将曾被认为在G6PD缺乏者中不安全的药物分为高、中、低至无风险三类。建议G6PD缺乏者避免高风险药物、慎用中风险药物、低至无风险药物可常规使用而不考虑G6PD表型。本文件替代了先前关于拉布立酶的CPIC指南。
要点
- G6PD基因型可用于G6PD缺乏症的诊断。
- 高风险药物应避免用于G6PD缺乏者。
- 中风险药物应慎用,低至无风险药物可常规使用。
核心结论
- G6PD缺乏者应避免高风险药物,慎用中风险药物,低至无风险药物可常规使用而不考虑G6PD表型。
研究设计与样本
- CPIC基于系统综述已发表的基因-药物关联证据和监管警告,对药物进行风险分类。
主要发现
- 将曾被认为在G6PD缺乏者中不安全的药物分为高风险、中风险、低至无风险三类。
关键数值与推荐
- 高风险药物:避免使用;中风险药物:慎用;低至无风险药物:可常规使用,无需考虑G6PD表型。
临床怎么用
- 使用G6PD基因型辅助诊断G6PD缺乏症,并根据药物风险分类指导用药选择。
局限性
- 许多药物的临床证据稀疏,且监管机构警告存在冲突。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia in the setting of oxidative stress, which can be caused by medication exposure. Regulatory agencies worldwide warn against the use of certain medications in persons with G6PD deficiency, but in many cases, this information is conflicting, and the clinical evidence is sparse. This guideline provides information on using G6PD genotype as part of the diagnosis of G6PD deficiency and classifies medications that have been previously implicated as unsafe in individuals with G6PD deficiency by one or more sources. We classify these medications as high, medium, or low to no risk based on a systematic review of the published evidence of the gene-drug associations and regulatory warnings. In patients with G6PD deficiency, high-risk medications should be avoided, medium-risk medications should be used with caution, and low-to-no risk medications can be used with standard precautions, without regard to G6PD phenotype. This new document replaces the prior Clinical Pharmacogenetics Implementation Consortium guideline for rasburicase therapy in the context of G6PD genotype (updates at: www.cpicpgx.org).
引用
- Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2022. PMID: 36049896. doi:10.1002/cpt.2735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。